Aurobindo Pharma Ltd. | AUROPHARMA | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
| 5,135 | 12,616 | 19,572 | 28,422 | 54,743 |
Short-term investment |
| 0.2 | 0.2 | 0.2 | 0.2 | 2,434 |
Accounts receivables |
| 35,042 | 30,844 | 34,138 | 43,152 | 35,033 |
Inventories |
| 43,305 | 58,584 | 72,456 | 76,999 | 90,266 |
Deferred income taxes |
| 175 | 646 | 346 | 158 | 790 |
Other current assets |
| 8,405 | 19,189 | 27,134 | 15,396 | 14,970 |
Total current assets |
| 92,062 | 121,878 | 153,645 | 164,125 | 198,235 |
Gross property plant... |
| 40,831 | 47,366 | 56,937 | 64,948 | 68,866 |
Accumulated Depriciat... |
| 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
| 40,831 | 47,366 | 56,937 | 64,948 | 68,866 |
Work in Progress |
| 12,374 | 13,995 | 13,419 | 16,218 | 24,289 |
Miscellaneous Investment |
| 3,267 | 4,044 | 4,560 | 6,776 | 5,818 |
Deferred income taxes |
| 2,257 | 2,414 | 3,214 | 2,463 | 5,809 |
Intangible assets |
| 5,652 | 11,511 | 22,752 | 23,498 | 26,907 |
Goodwill |
| 4,063 | 8,166 | 8,325 | 9,159 | 4,289 |
Other long-term assets |
| 1,989 | 1,678 | 1,691 | 2,076 | 4,327 |
Total non-current assets |
| 70,432 | 89,174 | 110,899 | 125,139 | 140,305 |
Total assets |
| 162,494 | 211,052 | 264,544 | 289,264 | 338,540 |
Short-term debt |
| 29,027 | 40,313 | 65,732 | 54,223 | 48,027 |
Accounts Payable... |
| 24,883 | 26,274 | 26,771 | 25,450 | 27,947 |
Provisions |
| 634 | 2,009 | 1,809 | 4,166 | 1,719 |
Taxes Payable |
| 265 | 431 | 663 | 1,282 | 2,104 |
Deferred Revenues |
| 0 | 0 | 0 | 0 | 0 |
Capital Leases |
| 0 | 0 | 0 | 0 | 0 |
Other current liabilities |
| 11,415 | 17,778 | 25,454 | 28,746 | 26,855 |
Total current liabilities |
| 66,223 | 86,806 | 120,429 | 113,868 | 106,651 |
Long-term debt |
| 1,814 | 4,512 | 1,800 | 0 | 1,684 |
Investments Liabilities |
| 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
| 493 | 2,353 | 2,813 | 3,025 | 5,746 |
Provisions |
| 224 | 559 | 465 | 747 | 1,571 |
Capital Leases |
| 0 | 0 | 0 | 2,644 | 2,662 |
Other longterm liabilities |
| 0 | 0 | 113 | 875 | 936 |
Total non-current liabilities |
| 2,531 | 7,423 | 5,191 | 7,291 | 12,599 |
Total liabilities |
| 68,754 | 94,230 | 125,620 | 121,158 | 119,250 |
Share Capital |
| 586 | 586 | 586 | 586 | 586 |
Share premium |
| 0 | 0 | 0 | 0 | 0 |
Retained earnings |
| 93,133 | 116,218 | 138,322 | 167,518 | 218,713 |
Accumulated other equity |
| 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
| 0 | 0 | 0 | 0 | 0 |
Minority Interest |
| 21 | 18 | 16 | 1 | -9 |
Total Equity |
| 93,740 | 116,822 | 138,924 | 168,105 | 219,290 |
Total Liabilities and Equity |
| 162,494 | 211,052 | 264,544 | 289,264 | 338,540 |
Cash per Share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |